Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.

Barnaby HuntSamuel J P MalkinRobert G J MoesEline L HuismanTom VandebrouckBruce H R Wolffenbuttel

Published in: BMJ open diabetes research & care (2019)

Once-weekly semaglutide is cost-effective versus insulin glargine U100, and dominant versus dulaglutide 0.75 and 1.5 mg for the treatment of type 2 diabetes, and represents a good use of healthcare resources in the Netherlands.

Keyphrases

healthcare
type diabetes
glycemic control
metabolic syndrome
adipose tissue
combination therapy
social media
data analysis